<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Despite the association of a worse HF-related clinical status with lower CoQ10 levels, the prognostic use of CoQ10 is controversial. The aim of this study is to optimize pharmacotherapy for patients with ischaemic CHF, based on the clinical and functional parameters of the heart and brain natriuretic peptide (BNP) plasma levels, which are correlated with the CoQ10 plasma levels, and to assess patient prognosis after receiving CoQ10 therapy. This prospective clinical study included 75 patients aged 56 to 63 years old with coronary heart disease (CHD) classified as class I–III according to the NYHA classification. After assessment of the clinical-instrumental characteristics of the CVD course (complaints, medical history, physical examination, a 6-minute walk test, echocardiography, and test for reactive hyperaemia), we determined the BNP level and CoQ10 plasma levels. At the same time, we assessed the efficacy of CoQ10 treatment (at a dose of 60 mg/per day) and tolerability in CVD-combined therapy during a follow-up of 12 weeks. CoQ10 supplementation in HF patients induced improvements in their functional cardiac parameters, such as the ejection fraction. Our results suggest that supplemental CoQ10 may be a useful option for effective management of heart failure and warrant future adequately powered randomized controlled trials of CoQ10 supplementation in patients with HF.</p></abstract>

Despite the association of a worse HF-related clinical status with lower CoQ10 levels, the prognostic use of CoQ10 is controversial. The aim of this study is to optimize pharmacotherapy for patients with ischaemic CHF, based on the clinical and functional parameters of the heart and brain natriuretic peptide (BNP) plasma levels, which are correlated with the CoQ10 plasma levels, and to assess patient prognosis after receiving CoQ10 therapy. This prospective clinical study included 75 patients aged 56 to 63 years old with coronary heart disease (CHD) classified as class I–III according to the NYHA classification. After assessment of the clinical-instrumental characteristics of the CVD course (complaints, medical history, physical examination, a 6-minute walk test, echocardiography, and test for reactive hyperaemia), we determined the BNP level and CoQ10 plasma levels. At the same time, we assessed the efficacy of CoQ10 treatment (at a dose of 60 mg/per day) and tolerability in CVD-combined therapy during a follow-up of 12 weeks. CoQ10 supplementation in HF patients induced improvements in their functional cardiac parameters, such as the ejection fraction. Our results suggest that supplemental CoQ10 may be a useful option for effective management of heart failure and warrant future adequately powered randomized controlled trials of CoQ10 supplementation in patients with HF.

Ubiquinone Plasma Levels are Correlated with Brain Natriuretic Peptide Plasma Levels in Patients with Chronic Heart Failure: The Potential of Coenzyme Q10 Combined Therapy

I.M. Sechenov First Moscow State Medical University (Sechenov University)

The Federal state budgetary institution “The Federal bureau for medical-social expertise” of Ministry of labour and social protection of the Russian Federation (FSBI FB MSE of Mintrud of Russia)

Experimental and Applied Biomedical Research (EABR)

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Despite the association of a worse HF-related clinical status with lower CoQ10 levels, the prognostic use of CoQ10 is controversial. The aim of this study is...

Ubiquinone Plasma Levels are Correlated with Brain Natriuretic Peptide Plasma Levels in Patients with Chronic Heart Failure: The Potential of Coenzyme Q10 Combined Therapy

Publié en ligne: 17 juil. 2018

Pages: 141 - 149

Reçu: 22 avr. 2018

Accepté: 24 avr. 2018

DOI: https://doi.org/10.2478/sjecr-2018-0012

Mots clés
coenzyme Q10-combined therapy, brain natriuretic peptide, chronic heart failure

© 2018 Zh.M. Sizova et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Ubiquinone Plasma Levels are Correlated with Brain Natriuretic Peptide Plasma Levels in Patients with Chronic Heart Failure: The Potential of Coenzyme Q10 Combined Therapy

Publié en ligne: 17 juil. 2018

Pages: 141 - 149

Reçu: 22 avr. 2018

Accepté: 24 avr. 2018

DOI: https://doi.org/10.2478/sjecr-2018-0012

Mots cléscoenzyme Q10-combined therapy, brain natriuretic peptide, chronic heart failure

© 2018 Zh.M. Sizova et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
coenzyme Q10-combined therapy, brain natriuretic peptide, chronic heart failure